View Complaint
Retainer Agreement
info@rosenlegal.com

Teva shareholders have an opportunity to recover their investment losses.

Click "Join this Class Action" above.

Attorneys

Teva Pharmaceutical Industries Ltd.

Rosen Law Firm, a global investor rights law firm, has filed a class action lawsuit on behalf of purchasers of Teva Pharmaceutical Industries Ltd. securities (NYSE: TEVA) from February 10, 2015 and November 3, 2016. The lawsuit seeks recovery of investor losses.

If you purchased shares of Teva from February 10, 2015 and November 3, 2016 and would like to join the action, please click "Join This Class Action" above.

Press Release

Rosen Law Firm Files Securities Class Action Lawsuit Against Teva Pharmaceutical Industries Limited - TEVA

New York, N.Y., November 6, 2016.  Rosen Law Firm, a global investor rights law firm, announces that it has filed a class action lawsuit on behalf of purchasers of the American Depositary Shares (“ADSs”) of Teva Pharmaceutical Industries Limited (NYSE: TEVA) between February 10, 2015 and November 3, 2016, both dates inclusive (the “Class Period”). The lawsuit seeks recovery of investor losses.

To join the Teva class action, go to the website at http://www.rosenlegal.com/cases-979.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or kchan@rosenlegal.com for information on the class action.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.

According to the lawsuit, throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) Teva was engaging and/or had engaged in conduct that would result in an antitrust investigation by the U.S. Department of Justice (“DOJ”) and the State of Connecticut Office of the Attorney General; (2) the DOJ investigation and the underlying conduct could cause U.S. prosecutors to file criminal charges against Teva by the end of 2016 for suspected price collusion; (3) in turn, Teva lacked effective internal controls over financial reporting; and (4) as a result, Teva’s public statements were materially false and misleading at all relevant times.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 5, 2017. If you wish to join the litigation, go to at http://www.rosenlegal.com/cases-979.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at pkim@rosenlegal.com or kchan@rosenlegal.com.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.

-------------------------------

Contact Information:

      Laurence Rosen, Esq.
      Phillip Kim, Esq.
      Kevin Chan, Esq.
      The Rosen Law Firm, P.A.
      275 Madison Avenue, 34th Floor
      New York, NY  10016
      Tel: (212) 686-1060
      Toll Free: (866) 767-3653
      Fax: (212) 202-3827
      lrosen@rosenlegal.com
      pkim@rosenlegal.com
      kchan@rosenlegal.com
      www.rosenlegal.com